Nada Hamad
A5081234421- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Cancer Risks and Factors
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- COVID-19 and healthcare impacts
- Childhood Cancer Survivors' Quality of Life
- Cytomegalovirus and herpesvirus research
- Vaccine Coverage and Hesitancy
- Multiple and Secondary Primary Cancers
- Neutropenia and Cancer Infections
- Mesenchymal stem cell research
- Polyomavirus and related diseases
- Eosinophilic Disorders and Syndromes
- Global Cancer Incidence and Screening
- Renal Transplantation Outcomes and Treatments
- Sex and Gender in Healthcare
St Vincent's Hospital Sydney
2018-2025
St Vincent's Clinic
2021-2025
UNSW Sydney
2018-2025
The University of Notre Dame Australia
2021-2025
The Kinghorn Cancer Centre
2019-2025
St Vincent's Hospital
2018-2025
The University of Sydney
2014-2024
St Vincent's Health
2019-2024
St. Vincent's Hospital
2023-2024
Saint Vincent's Catholic Medical Center
2023-2024
Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved diffuse large lymphoma at least two treatment lines.
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries individual centers. In 2016, 82,718 first HCT were reported 1,662 teams in 86 195 World Health Organization states representing a global increase 6.2% autologous 7.0% allogeneic bringing total to 1,298,897 procedures. Assuming frequency 84,000/year, 1.5 million performed 2019...
Tebotelimab, a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 and LAG-3, was investigated for clinical safety activity in phase 1 dose-escalation cohort-expansion trial patients with solid tumors or hematologic malignancies disease progression on previous treatment. Primary endpoints were maximum tolerated dose of tebotelimab when administered as single agent (n = 269) combination the anti-HER2 antibody margetuximab 84). Secondary included anti-tumor activity. In advanced cancer...
As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications international access improves, the number of HCTs performed annually continues rise. Parallel improvements in HCT techniques supportive care entails more patients surviving long term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary pretransplantation, peritransplantation, post-transplantation exposures other underlying factors....
<h3>Importance</h3> Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy autologous hematopoietic cell transplant (AHCT) is an accepted effective strategy for PCNSL, but no consensus exists on the optimal conditioning regimens. <h3>Objective</h3> To assess outcomes in patients with PCNSL undergoing AHCT 3 most commonly used regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmustine (TT-BCNU),...
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment for myelofibrosis. However, optimal conditioning regimen either with reduced-intensity (RIC) or myeloablative (MAC) is not well known. Using Center International Blood and Marrow Transplant Research database, we identified adults aged ≥18 years myelofibrosis undergoing allo-HCT between 2008-2019 analyzed outcomes separately in RIC MAC cohorts based on regimens used. Among 872 eligible patients, 493...
PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There no consensus regarding the optimal approach to prophylaxis. This study was designed determine whether high-dose methotrexate (HD-MTX) effective at preventing in patients high risk this complication. PATIENTS AND METHODS Patients age 18-80 years with lymphoma and progression, treated curative-intent anti–CD20-based chemoimmunotherapy, were included international, retrospective,...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors immunoarchitectural patterns (IAPs) for all stages pediatric adult patients with NLPHL.
Abstract The COVID‐19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known cause disproportionately severe disease in cancer, and lymphoma, myeloma chronic lymphocytic leukaemia are likely be at particular risk related COVID‐19. This statement has been developed by consensus among authors from Australia New Zealand. We aim provide supportive guidance clinicians making individual patient decisions during pandemic, periods that...
Summary Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL ibrutinib. We analysed 33 patients who received ibrutinib, alone or other therapies, for PCNSL ( n = 9) SCNSL 24). The objective response rate was 58% (complete 55%). median progression‐free survival overall were both 3·1 months; SCNSL, 10·2 11·5 months...
As COVID-19 vaccinations became available and were proven effective in preventing serious infection, uptake amongst individuals varied, including medically vulnerable populations. This cross-sectional multi-site study examined vaccine uptake, hesitancy, explanatory factors people with and/or chronic health conditions, the impact of underlying disease on attitudes to vaccination. A 42-item survey was distributed cancer, diabetes, or multiple sclerosis across ten Australian services from 30...
From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide individual Centers with a means quality-assuring the HSCT process meeting FACT-JACIE accreditation requirements relating 1-year survival outcomes. Informed by previous experience from Europe, North America Australasia, Clinical Outcomes Group (COG) established criteria for patient Center selection, set key clinical variables within dedicated...
Abstract Background The incidence of pregnancy-associated cancer (PAC), comprising diagnosed during pregnancy or within one year postpartum, is increasing. We investigated the obstetric management and outcomes women with PAC their babies. Methods A population-based observational study all who gave birth between 1994 2013 in New South Wales, Australia. Women were stratified into three groups: those (gestational group), giving (postpartum a no-PAC group. Generalized estimating equations used...
Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting disseminating data on global HCT activities is one of the principal Worldwide Network for Blood Marrow Transplantation, a non-governmental organization working relations with World Health Organization. are recorded annually member societies, national registries individual centers including indication, donor type (allogeneic/autologous), match stem source (bone marrow/peripheral blood cells/cord...
We evaluate the impact of donor types on outcomes hematopoietic cell transplantation (HCT) in myelofibrosis, using Center for International Blood and Marrow Transplant Research registry data HCTs done between 2013 2019. In all 1597 patients, use haploidentical donors increased from 3% to 19% study-eligible 1032 patients who received peripheral blood grafts chronic-phase 38% recipients HCT were non-White/Caucasian. Matched sibling (MSD)-HCTs associated with superior overall survival (OS)...
Abstract Anaemia is a well‐recognised and widely accepted consequence of iron deficiency (ID); however, the two diagnoses are not synonymous with effects ID occurring long before development anaemia. In adults, can cause physical neuropsychological symptoms, including lethargy, altered mood poor concentration, reducing an individual's quality life. Foetal neonatal has been associated impaired neurocognitive lasting despite replacement in early Obstetric common, affecting up to 70% Australian...
Background: Cancer treatment can significantly reduce reproductive potential in female patients. This study sought to explore the incidence of fertility counseling women childbearing before, during, and after anticancer therapies. Methods: We conducted a retrospective medical record review at major Australian cancer center premenopausal females aged 18 49 years diagnosed with between 2017 2020. Results: A total 143 patients met inclusion criteria. Of these patients, only 12.6% had health...